← Leaderboards
Yi Li
Baylor College Of Medicine
$11,171,360
Attributed
$12,438,936
Total exposure
9
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,438,936 · 9
By mechanism
R01$10,667,557 · 6
P50$1,352,151 · 1
R21$379,212 · 1
P20$40,016 · 1
Top collaborators
- Xiang Zhang5 shared
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Jeffrey Rosen$27,294,929
- Suzanne A Fuqua$14,426,929
- Pavel Sumazin$795,451
- Donna I Myers$4,462
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsMalignant Breast NeoplasmMammary NeoplasmsTumorLesionSignal TransductionMammary GlandCellsOncogenesBreastPreventIn VivoMutationTumorigenesisPremalignantOncogenicGeneticOverexpressionRattusWomanMediatingReportingApoptosisMolecular
Grant awards (36)
Next Generation Rat Models of ER+ Breast Cancer$595,831
R01 · FY2025 · CA · contact PI
Lactation on Breast Tumorigenesis$523,284
R01 · FY2025 · CA · contact PI
Racial and social contextual factors in relation to epigenome and bladder cancer outcome.$40,016
P20 · FY2025 · CA · contact PI
Next Generation Rat Models of ER+ Breast Cancer$567,317
R01 · FY2024 · CA · contact PI
Lactation on Breast Tumorigenesis$497,126
R01 · FY2024 · CA · contact PI
Next Generation Rat Models of ER+ Breast Cancer$585,230
R01 · FY2023 · CA · contact PI
Lactation on Breast Tumorigenesis$553,286
R01 · FY2023 · CA · contact PI
Mutating E-cadherin in rats to model lobular breast cancer$174,600
R01 · FY2023 · CA · contact PI
Next Generation Rat Models of ER+ Breast Cancer$612,175
R01 · FY2022 · CA · contact PI
A Novel LGR4 Oncogenic Signaling in Breast Cancer Progression and Metastasis$362,569
R01 · FY2021 · CA · contact PI
Ruxolitinib for Preventing Breast Cancer in Women on Neuroleptics$362,569
R01 · FY2021 · CA · contact PI
Ruxolitinib for Preventing Breast Cancer in Women on Neuroleptics$362,569
R01 · FY2020 · CA · contact PI
A Novel LGR4 Oncogenic Signaling in Breast Cancer Progression and Metastasis$362,569
R01 · FY2020 · CA · contact PI
Ruxolitinib for Preventing Breast Cancer in Women on Neuroleptics$351,691
R01 · FY2019 · CA · contact PI
A Novel LGR4 Oncogenic Signaling in Breast Cancer Progression and Metastasis$351,691
R01 · FY2019 · CA · contact PI
Ruxolitinib for Preventing Breast Cancer in Women on Neuroleptics$362,569
R01 · FY2018 · CA · contact PI
A Novel LGR4 Oncogenic Signaling in Breast Cancer Progression and Metastasis$362,569
R01 · FY2018 · CA · contact PI
Intermittent Ruxolitinib to Target STATS Activation for Breast Cancer Prevention$284,259
P50 · FY2018 · CA · contact PI
A Novel LGR4 Oncogenic Signaling in Breast Cancer Progression and Metastasis$362,569
R01 · FY2017 · CA · contact PI
Ruxolitinib for Preventing Breast Cancer in Women on Neuroleptics$362,569
R01 · FY2017 · CA · contact PI
Intermittent Ruxolitinib to Target STATS Activation for Breast Cancer Prevention$285,772
P50 · FY2017 · CA · contact PI
The cell of origin of breast cancer metastasis$206,843
R21 · FY2017 · CA · contact PI
Intermittent Ruxolitinib to Target STATS Activation for Breast Cancer Prevention$267,203
P50 · FY2016 · CA · contact PI
The cell of origin of breast cancer metastasis$172,369
R21 · FY2016 · CA · contact PI
Intermittent Ruxolitinib to Target STATS Activation for Breast Cancer Prevention$259,158
P50 · FY2015 · CA · contact PI
Oncogene susceptibility: physiological state & breast cell differentiation$299,692
R01 · FY2014 · CA · contact PI
Intermittent Ruxolitinib to Target STATS Activation for Breast Cancer Prevention$255,759
P50 · FY2014 · CA · contact PI
Oncogene susceptibility: physiological state & breast cell differentiation$290,420
R01 · FY2013 · CA · contact PI
Oncogene susceptibility: physiological state & breast cell differentiation$308,957
R01 · FY2012 · CA · contact PI
Oncogene susceptibility: physiological state & breast cell differentiation$308,957
R01 · FY2011 · CA · contact PI
Oncogene susceptibility: physiological state & breast cell differentiation$318,513
R01 · FY2010 · CA · contact PI
PROGENITOR CELLS AND ONCOGENE TARGETS IN BREAST CANCER$280,899
R01 · FY2009 · CA · contact PI
PROGENITOR CELLS AND ONCOGENE TARGETS IN BREAST CANCER$280,899
R01 · FY2008 · CA · contact PI
PROGENITOR CELLS AND ONCOGENE TARGETS IN BREAST CANCER$280,899
R01 · FY2007 · CA · contact PI
PROGENITOR CELLS AND ONCOGENE TARGETS IN BREAST CANCER$289,288
R01 · FY2006 · CA · contact PI
PROGENITOR CELLS AND ONCOGENE TARGETS IN BREAST CANCER$296,250
R01 · FY2005 · CA